موافقات الدواء

Tecartus is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:
• Mantle Cell Lymphoma
Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.
• Acute Lymphoblastic Leukemia
Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).